Skip to main
BAX
BAX logo

Baxter (BAX) Stock Forecast & Price Target

Baxter (BAX) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 67%
Sell 11%
Strong Sell 0%

Bulls say

Baxter International's stock outlook is bolstered by solid growth in its Healthcare Systems & Technologies segment, with recorded sales increases of approximately 6% in 1Q25 and 2% in 2Q25, alongside expectations for continued growth in the latter half of 2025. The positive trajectory is further supported by pricing initiatives projected to yield an additional 100 basis points of sales growth during 2024 and 2025. Expanding its portfolio through the acquisition of Hillrom has diversified Baxter's offerings, allowing for continued innovation and market adaptation amidst evolving healthcare demands.

Bears say

Baxter International's financial performance in the second quarter of 2025 reflected a significant decline, with sales, margins, and earnings per share all falling short of consensus expectations. The company has faced a series of operational challenges from 2021 to 2023, resulting in inconsistent quarterly results and downward guidance revisions. Additionally, a combination of sales softness, manufacturing inefficiencies, and an unfavorable product mix led to gross margins of 40.7%, which missed the consensus of 42.7% and operating margins of 15.1%, falling below consensus by over 100 basis points.

Baxter (BAX) has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Baxter (BAX) Forecast

Analysts have given Baxter (BAX) a Hold based on their latest research and market trends.

According to 9 analysts, Baxter (BAX) has a Hold consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Baxter (BAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.